NouvNeu001, A Phase 1 Stage Chemically Induced Human Dopaminergic Progenitor Cell Therapy for the Treatment of Mid- to Late-stage Parkinson’s Disease
Objective: To access the efficacy and safety of NouvNeu001 in models of Parkinson’s Disease (PD) and a Phase 1 clinical trial (NCT#06167681). Background: Parkinson's disease…Bioreactor-produced iPSCs-derived Dopaminergic Neuron-containing Neural Microtissues Innervate and Restore Motor Function in a Dose-dependent Manner in a Parkinson Rat Model
Objective: To demonstrate the efficacy of a ready-to-graft 3D neural microtissue product – manufactured at large scale – as a therapeutically viable option to treat Parkinson’s…Safety and Tolerability of Bemdaneprocel in People With Parkinson’s Disease: Results up to 24 Months From a Phase 1 Study
Objective: To report the safety and tolerability of bemdaneprocel in participants with Parkinson’s disease (PD) up to 24 months post transplantation. Background: Bemdaneprocel is an…Motor and Non-Motor Outcomes of Bemdaneprocel in People With Parkinson’s Disease: Results up to 24 Months From a Phase 1 Study
Objective: To describe the effects of bemdaneprocel on motor and non-motor outcomes in participants with Parkinson’s disease (PD) up to 24 months post transplantation (12…Dopaminergic neuronal cell therapy for Parkinson’s Disease: results from a phase 1 study of Bemdaneprocel
Objective: This first-in-human Phase 1 study aims to assess the safety, tolerability, clinical efficacy, and functional imaging measures of bemdaneprocel in subjects with PD. Background:…hUC-MSCs ameliorated CUMS-induced depression by modulating complement C3 signaling-mediated microglial polarization during astrocyte-microglia crosstalk
Objective: To demonstrate whether hUC-MSCs can benefit depressive-like behavior by altering C3/C3a-C3aR signaling to impact microglia polarization in the CUMS model. Background: Major depressive disorder (MDD) has been…Distribution of intranasal hNSCs in a mouse model of MPTP-induced Parkinson’s disease
Objective: We aimed to map the distribution of human neural stem cells (hNSCs) in the brain and peripheral tissues after intranasal administration in a mouse…Two-year outcome of autologous peripheral nerve grafting to the substantia nigra at the time of DBS surgery in patients with Parkinson’s disease
Objective: Assess 2-year safety, feasibility, and clinical outcomes of implanting a unilateral peripheral nerve graft to the substantia nigra in patients with Parkinson’s disease at…Evidence of survival and integration of implanted autologous peripheral nerve graft in substantia nigra in a patient with Parkinson’s disease
Objective: We report a patient with Parkinson’s disease (PD) who underwent deep brain stimulation (DBS) simultaneously with peripheral nerve graft in substantia nigra (SN) and the…Investigating the impact of a-synuclein pathology on human embryonic stem cell derived dopaminergic neurons transplanted in an accelerated a-synuclein rat model of Parkinson’s disease
Objective: In this study, we assess how transplanted human embryonic stem cell (hESC) derived dopaminergic (DA) neurons survive, mature, integrate and innervate the host circuitry…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.